

Technical Bulletin

DLS Molecular Transport Media for SARS-CoV-2 (COVID-19) Validated for Influenza A/B and RSV at DLS Central Facility

TO:	Medical Staff and Clients		
FROM:	Dr. Wesley Kim, MD		
	Medical Director, DLS and QMC West		
	Dr. Amy Woron, PhD Manager, DLS Molecular	Dr. A. Christian Whelen, PhD VP & Technical Director Microbiology & Molecular	Dr. Ana Ortega-Lopez, MD Medical Director QMC Punchbowl, North Hawaii and Molokai
DATE:	December 29, 2020	6,	
SUBJECT:	DLS PCR collection kits now validated for SARS-CoV-2 (COVID-19), Influenza A/B, and RSV		

Effective December 28, 2020, DLS began accepting DNA/RNA Shield Transport Media for **SARS-CoV-2**, **Influenza**, **and Respiratory Syncytial Virus (RSV)** PCR testing at the DLS Central Facility in Halawa. These collection kits contain transport media that quickly inactivates microbes like SARS-COV-2, but also preserves nucleic acids, which PCR is designed to detect.

These kits can be used for both symptomatic (influenza-like illness) and asymptomatic screens (e.g., travelers, students, and employees). It is compatible with test system at DLS Central ONLY, and <u>NOT with hospital test systems</u> (e.g., Cepheid GeneXpert, BD Max, Abbott ID Now, and Roche Liat).

This media is NOT compatible for testing with BioFire Film Array multiplex panels or virus culture.

There are no changes to the test codes:

Test:	SARS-CoV-2 (COVID-19), Influenza A/B, RSV performed at Central ONLY
DLS Order code:	7179 (COVID)
	7223 (non-medical COVID)
	6234 (Influenza A/B)
	6255 (Influenza A/B, RSV)
Specimen:	Nasopharyngeal, Oropharyngeal, or nasal swabs.
Transport/Stability:	Room Temperature (or refrigerated) for 72 HOURS or Frozen at -70°F
Turnaround time:	< 3 days (normally 12-36 hours from receipt in the lab); NOT available STAT

Clients will be notified of a "Detected" result

It is important to remember that even if a patient is suspected to have SARS-CoV-2, rapid testing for other common organisms such as influenza remains an integral part of the workup process. Validation of this media for influenza and RSV was successful at DLS Central.

Please refer any questions to DLS Client Services at 589-5101 or Dr. Amy Woron, Manager - DLS Microbiology Lab at 441-5436

https://www.cdc.gov/coronavirus/2019-ncov/index.html https://health.hawaii.gov/docd/advisories/novel-coronavirus-2019/

Diagnostic Laboratory Services Inc. 99-859 Iwaiwa Street – Aiea, HI 96701 (808) 589-5100 – www.dlslab.com